Market capitalization | $5.87m |
Enterprise Value | $-6.27m |
PER (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.67 |
P/B ratio (TTM) P/B ratio | 0.47 |
Turnover (TTM) Turnover | $0.00 |
EBIT (operating result TTM) EBIT | $-10.60m |
Free cash flow (TTM) Free cash flow | $-9.34m |
Cash position | $12.55m |
As a free StocksGuide basic user, you can view the scores for all 6,953 shares worldwide.
1 Analyst has issued a forecast Tenax Therapeutics, Inc.:
1 Analyst has issued a forecast Tenax Therapeutics, Inc.:
Mar '24 |
+/-
%
|
||
Net profit | -10 -10 |
4%
4%
|
|
Depreciation and amortization | 0.01 0.01 |
89%
89%
|
|
Share compensation | 0.24 0.24 |
31%
31%
|
|
Operating cash flow | -9.34 -9.34 |
13%
13%
|
|
Investments | - - |
-
|
|
Dividend paid | - - |
-
|
|
Free cash flow | -9.34 -9.34 |
-
|
Figures in millions USD.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
Tenax Therapeutics, Inc. engages in the identification, development, and commercialization of novel therapeutic products for the critical care market. Its lead product candidate is Levosimendan, a calcium sensitizer activator for intravenous use in hospitalized patients with acutely decompensated heart failure. The company was founded on May 26, 1967 and is headquartered in Morrisville, NC.
Head office | United States |
CEO | Christopher Giordano |
Employees | 5 |
Founded | 1967 |
Website | www.tenaxthera.com |
StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.